---
title: "小鵬發佈 SEPA 2.0（扶搖）架構，目前有 10 款車型正在研發"
description: "華爾街見聞 4 月 16 日獲悉，小鵬發佈 SEPA 2.0（扶搖）架構。據小鵬汽車董事長何小鵬透露，目前小鵬汽車內部有 10 款車型正在研發，基於扶搖框架，新車研發週期將縮短 20%，零部件通用化率提升至 80%，整車綜合研發成本降低 50%。（見聞 auto）"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/85202439.md"
published_at: "2023-04-16T07:45:42.000Z"
---

# 小鵬發佈 SEPA 2.0（扶搖）架構，目前有 10 款車型正在研發

> 華爾街見聞 4 月 16 日獲悉，小鵬發佈 SEPA 2.0（扶搖）架構。據小鵬汽車董事長何小鵬透露，目前小鵬汽車內部有 10 款車型正在研發，基於扶搖框架，新車研發週期將縮短 20%，零部件通用化率提升至 80%，整車綜合研發成本降低 50%。（見聞 auto）

華爾街見聞 4 月 16 日獲悉，小鵬發佈 SEPA 2.0（扶搖）架構。據小鵬汽車董事長何小鵬透露，目前小鵬汽車內部有 10 款車型正在研發，基於扶搖框架，新車研發週期將縮短 20%，零部件通用化率提升至 80%，整車綜合研發成本降低 50%。（見聞 auto）

### Related Stocks

- [XPEV.US - 小鵬汽車](https://longbridge.com/zh-HK/quote/XPEV.US.md)
- [09868.HK - 小鵬汽車-W](https://longbridge.com/zh-HK/quote/09868.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Xpeng secures L3 autonomous driving road test permits in Guangzhou | Xpeng has secured L3 autonomous driving road test permits in Guangzhou, marking a significant regulatory update in China | [Link](https://longbridge.com/zh-HK/news/269821815.md) |
| XPEV Earnings: XPeng Stock Falls Despite Narrower Q3 Loss and Solid Margins. Here's Why | XPeng (XPEV) reported a narrower Q3 loss and improved margins, with revenue up 101.8% year-over-year. Despite this, XPEV | [Link](https://longbridge.com/zh-HK/news/266175267.md) |
| ROI-West needs its own pricing to escape China's rare earths grip: Andy Home | A recent surge in rare earth prices has lifted them above the U.S. government's guaranteed floor price for MP Materials, | [Link](https://longbridge.com/zh-HK/news/276459435.md) |
| Musk unveils Tesla Cybercab price as robotaxi push grows | Musk unveils Tesla Cybercab price as robotaxi push grows | [Link](https://longbridge.com/zh-HK/news/276393415.md) |
| Xpeng reveals GX as new flagship SUV | Xpeng, a Chinese EV maker, is set to launch its new flagship six-seater SUV, the GX, in China. The model will be availab | [Link](https://longbridge.com/zh-HK/news/276145922.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。